Zacks Investment Research upgraded shares of ChemoCentryx, Inc. (NASDAQ:CCXI) from a hold rating to a buy rating in a report published on Monday, July 17th. Zacks Investment Research currently has $12.00 target price on the biopharmaceutical company’s stock.
According to Zacks, “ChemoCentryx, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. ChemoCentryx, Inc. is headquartered in Mountain View, California. “
Shares of ChemoCentryx (NASDAQ:CCXI) remained flat at $9.96 during trading on Monday. 78,695 shares of the company’s stock traded hands. ChemoCentryx has a 1-year low of $3.95 and a 1-year high of $10.68. The company has a 50 day moving average price of $9.06 and a 200-day moving average price of $7.60. The firm’s market capitalization is $479.80 million.
ChemoCentryx (NASDAQ:CCXI) last issued its quarterly earnings data on Wednesday, May 10th. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.14. The company had revenue of $8.23 million for the quarter. On average, equities analysts anticipate that ChemoCentryx will post ($0.69) earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Zacks Investment Research Upgrades ChemoCentryx, Inc. (CCXI) to Buy” was reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this news story on another website, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://stocknewstimes.com/2017/07/30/chemocentryx-inc-ccxi-upgraded-at-zacks-investment-research-updated.html.
In other ChemoCentryx news, insider Petrus Bekker sold 76,013 shares of the stock in a transaction dated Thursday, July 13th. The stock was sold at an average price of $9.95, for a total value of $756,329.35. Following the completion of the sale, the insider now directly owns 65,963 shares in the company, valued at $656,331.85. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Roger C. Lucas sold 4,000 shares of the stock in a transaction dated Monday, May 1st. The shares were sold at an average price of $7.31, for a total value of $29,240.00. Following the completion of the sale, the director now owns 62,822 shares of the company’s stock, valued at $459,228.82. The disclosure for this sale can be found here. Insiders have sold a total of 225,399 shares of company stock valued at $2,163,943 over the last 90 days. 26.80% of the stock is currently owned by company insiders.
A number of large investors have recently added to or reduced their stakes in the stock. Bank of Montreal Can acquired a new stake in ChemoCentryx during the second quarter worth approximately $102,000. Dynamic Technology Lab Private Ltd acquired a new stake in ChemoCentryx during the first quarter worth approximately $189,000. First Quadrant L P CA acquired a new stake in ChemoCentryx during the second quarter worth approximately $219,000. American Century Companies Inc. acquired a new stake in ChemoCentryx during the first quarter worth approximately $297,000. Finally, Teachers Advisors LLC boosted its stake in ChemoCentryx by 8.4% in the fourth quarter. Teachers Advisors LLC now owns 40,288 shares of the biopharmaceutical company’s stock worth $298,000 after buying an additional 3,114 shares during the period. Institutional investors own 49.37% of the company’s stock.
ChemoCentryx Company Profile
ChemoCentryx, Inc is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact.
Get a free copy of the Zacks research report on ChemoCentryx (CCXI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ChemoCentryx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
